Health
Convalescent plasma treatment added to Australian COVID-19 trials – Medical Xpress
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat …
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalized with COVID-19.
The first patient was recruited to ASCOT earlier this week at The Royal Melbourne Hospital, while REMAP-CAP is on schedule to recruit critically ill patients in partnering Intensive Care Units in the com…
-
Noosa News19 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News21 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
Noosa News17 hours agoFranz Ferdinand: Australian Tour 2025
-
Business17 hours agoHow these 5 ASX 200 stocks are smashing the benchmark this week